Skip to content

Oral povorcitinib: 75% facial repigmentation in ~19% vs 3-7%

November 7, 2026 · 9 min

Show notes

Editor's Pick: Povorcitinib for nonsegmental vitiligo: two randomized, controlled, phase 3 STOP-V trials (Nature Medicine, 2026)

This AudioScholar briefing is generated by artificial intelligence for healthcare professionals and trainees. It is not medical advice.

Welcome to This Week in Dermatology. This week we're covering 10 notable papers spanning systemic therapy for chronic inflammatory skin disease, the rising burden of bullous pemphigoid, and pediatric care alongside treatment resistance in scabies and melanoma. Let's dive in.

This week's papers:

  1. Povorcitinib for nonsegmental vitiligo: two randomized, controlled, phase 3 STOP-V trials.. Nature Medicine 2026
  2. Risk of cancer in psoriasis patients treated with biologic therapy: A BADBIR cohort study.. Journal of the European Academy of Dermatology and Venereology 2026
  3. Dupilumab in Atopic Dermatitis - Rate of Poor Responders and Potential Risk Factors from the TREATgermany Registry.. Acta Dermato-Venereologica 2026
  4. End-of-Dose Effect as a Guide for Biologic Optimization in Hidradenitis Suppurativa.. JAMA Dermatology 2026
  5. Increased incidence and healthcare burden of bullous pemphigoid: A population-based cohort study.. Journal of the European Academy of Dermatology and Venereology 2026
  6. Dipeptidyl Peptidase-4 Inhibitors and Bullous Pemphigoid: A Danish Nationwide Case-Control Study.. Dermatology 2026
  7. Clinical Outcomes of Nasal Tip Infantile Hemangiomas: A Retrospective Cohort Study.. Pediatric Dermatology 2026
  8. Expert Recommendations for Use of Combined Oral Contraceptives in Preadolescent and Young Adolescent Patients With Acne Vulgaris.. Pediatric Dermatology 2026
  9. Ineffectiveness of permethrin in human scabies treatment: A multicenter study of kdr gene mutations.. Journal of the European Academy of Dermatology and Venereology 2026
  10. Regulatable membrane-bound IL-15 engineered TIL cell therapy for immune checkpoint inhibitor-resistant advanced melanoma: pooled analysis of phase 1 and 1/2 trials.. Nature Medicine 2026

Listen at AudioScholar

All episodes of AudioScholar Dermatology Weekly (India)

Settings

Display

Language

Decides which stations you see first on the home page.

History

Recently played stations and episodes and your latest searches are only stored in this browser.

Notifications

A short notice when a podcast you follow has a new episode. Turn off single podcasts with the bell on their page.

Account

Save favorites – in the app and on the website.

Keyboard shortcuts

/
Open search
Space
Play or pause
← →
In the player: back 15 s, forward 30 s (episodes) · in a row: next tile
↑ ↓
In a row: target within the tile
Home / End
In a row: first or last tile
Esc
Close window or menu
?
This overview
Now playing

Go to station page

Play next

    Add episodes with “Play next” – they play after the current episode.